NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Clinical trials for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) explained in plain language.
Never miss a new study
Get alerted when new NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) trials appear
Sign up with your email to follow new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug, ADU-1805, in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or with another cancer drug (pembrolizumab). The main goals are to check safety and how the body processes the drug. Abo…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1 • Sponsor: Sairopa B.V. • Aim: Disease control
Last updated May 26, 2026 02:22 UTC
-
New hope for Hard-to-Treat lung cancer: targeted pill takes on chemo
Disease control Recruiting nowThis study tests a new oral drug, RMC-6236, against standard chemotherapy (docetaxel) in 420 adults with advanced non-small cell lung cancer that has a specific RAS mutation and has already been treated. The goal is to see if the new drug can delay cancer growth and extend life. …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 26, 2026 02:21 UTC
-
New drug ALX2004 targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called ALX2004 in people with advanced lung, head and neck, colorectal, or esophageal cancers that have stopped responding to standard treatments. ALX2004 is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1 • Sponsor: ALX Oncology Inc. • Aim: Disease control
Last updated May 26, 2026 02:21 UTC
-
New combo attack for tough lung cancer shows promise in early trial
Disease control Recruiting nowThis study is for people with advanced non-small cell lung cancer whose disease got worse after initial immunotherapy and chemotherapy. It tests a combination of microwave ablation (using heat to destroy tumors) plus two drugs (tislelizumab and docetaxel) to see if it can control…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 26, 2026 02:21 UTC
-
New pill shows promise against tough lung cancer mutations in phase 3 trial
Disease control Recruiting nowThis study tests a new daily pill, firmonertinib, against standard chemotherapy for people with advanced non-small cell lung cancer that has certain EGFR mutations (PACC or L861Q). About 300 participants will be randomly assigned to receive either the pill or chemo. The goal is t…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 02:18 UTC
-
New pill hopes to tackle tough lung cancer
Disease control Recruiting nowThis early-stage study tests a new tablet, HJ-004-02, in people with advanced non-squamous non-small cell lung cancer that has specific EGFR mutations. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. About 36 adults who have tried …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1 • Sponsor: Tongji University • Aim: Disease control
Last updated May 26, 2026 02:15 UTC
-
New combo shields bone marrow in tough lung cancer cases
Disease control Recruiting nowThis study tests whether giving a bone marrow-protecting drug (trilaciclib) before chemotherapy (sacituzumab tirumotecan) can reduce serious side effects like low white blood cell counts in people with advanced EGFR-mutant lung cancer that stopped responding to prior treatments. …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated May 26, 2026 02:09 UTC
-
New combo therapy aims to outsmart resistant lung cancer
Disease control Recruiting nowThis study tests whether adding a new drug called QL1706 (which blocks two immune checkpoints at once) to standard chemotherapy can help people with advanced non-small cell lung cancer whose disease got worse after initial immunotherapy. About 96 adults aged 18-75 with no EGFR or…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated May 26, 2026 02:07 UTC
-
New combo therapy aims to tame tough cancers
Disease control Recruiting nowThis study tests a new drug called TCC1727 combined with other cancer treatments (benmelstobart, olaparib, or topotecan) in people with advanced solid tumors like lung, stomach, endometrial, or melanoma. The goal is to find the safest and most effective dose and see if the combin…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Beijing Tide Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New dosing strategy may boost drug levels in the brain for advanced lung cancer
Disease control Recruiting nowThis study tests whether taking a higher dose of the targeted drug furmonertinib every other day can better control lung cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis). About 42 adults with a specific EGFR gene mutation will choose e…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: NA • Sponsor: Guangzhou University of Traditional Chinese Medicine • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Poop pills may restore cancer drug power in lung patients
Disease control Recruiting nowThis study tests whether taking a special fecal transplant (MaaT033) alongside the immunotherapy drug cemiplimab can help overcome resistance caused by prior antibiotic use in people with advanced non-small cell lung cancer. About 162 participants will be randomly assigned to rec…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New hope for lung cancer: targeted drug BH-30643 enters human trials
Disease control Recruiting nowThis study tests a new drug, BH-30643, in adults with advanced non-small cell lung cancer that has certain gene changes (EGFR or HER2 mutations). The goal is to find a safe dose and see if the drug shrinks tumors. About 266 people will take part across multiple centers.
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1, PHASE2 • Sponsor: BlossomHill Therapeutics • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new treatment called CAR-T cells that are designed to find and attack cancer cells carrying a protein called CEA. The study includes adults with advanced non-small cell lung cancer or breast cancer that has not responded to standard treatments.…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New hope for hard-to-treat cancers? drug combo trial begins
Disease control Recruiting nowThis study tests a new drug called ODM-212 combined with other anti-cancer treatments in people with advanced solid tumors, including mesothelioma, pancreatic cancer, and non-small cell lung cancer. The trial has two parts: first finding a safe dose, then checking how well it wor…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Orion Corporation, Orion Pharma • Aim: Disease control
Last updated May 18, 2026 12:11 UTC
-
New hope for drug-resistant lung cancer: targeted radiation plus four-drug combo enters trial
Disease control Recruiting nowThis study tests whether adding precise radiation to a four-drug combination can help people with advanced EGFR-mutant lung cancer whose first treatment stopped working. About 53 adults will receive the drugs (sintilimab, bevacizumab, platinum, pemetrexed) plus personalized radia…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New study digs deeper into Long-Term benefits of immunotherapy combo for lung cancer
Knowledge-focused Recruiting nowThis study collects long-term survival data from 109 patients with advanced squamous non-small cell lung cancer who previously received tislelizumab combined with chemotherapy in the RATIONALE-307 trial. The goal is to better understand long-term benefits and identify which patie…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated May 26, 2026 02:20 UTC
-
Italian study maps rare HER2 mutations in advanced lung cancer
Knowledge-focused Recruiting nowThis study is observing people with advanced non-small cell lung cancer (NSCLC) in Italy to find out how common HER2 mutations are and how doctors currently treat them. About 50 participants will be followed for one year. The goal is to gather real-world information, not to test …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica • Aim: Knowledge-focused
Last updated May 26, 2026 02:18 UTC
-
Lung cancer genes linked to blood clot danger in new study
Knowledge-focused Recruiting nowThis study looks at whether certain gene changes in advanced lung cancer increase the risk of dangerous blood clots. Researchers will follow 500 people with stage III or IV non-small-cell lung cancer for 6 months, measuring blood markers and tracking clot events. The goal is to l…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: University Of Perugia • Aim: Knowledge-focused
Last updated May 26, 2026 02:13 UTC
-
AI-Powered radiation plans could cut waiting time for lung cancer patients
Knowledge-focused Recruiting nowThis study looks at whether new AI tools can make radiation treatment planning faster and more comfortable for people with advanced lung cancer. Researchers will measure how long each step takes and check if using daily scan images instead of extra CT scans works just as well. Ab…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: NA • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated May 19, 2026 12:00 UTC